Ozempic FDA-Approved to Lower Kidney Disease Risk in Diabetic Patients - iData Research
US FDA approved Novo Nordisk to use their GLP-1 drug, Ozempic, to reduce the risk of kidney failure and kidney disease progression.| iData Research
US FDA approved Novo Nordisk to use their GLP-1 drug, Ozempic, to reduce the risk of kidney failure and kidney disease progression.| iData Research
Discover the top 5 diabetes drugs in 2025, including GLP-1 receptor agonists, once-weekly insulin, and SGLT2 inhibitors.| iData Research
